Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: How does it actually compare to factor VIII?

Blood

Volumn 130, Issue 23, 2017, Pages 2463-2468

  Lenting, Peter J ^a   Denis, Cécile V ^a   Christophe, Olivier D ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; EMICIZUMAB; ENZYME PRECURSOR; BLOOD CLOTTING FACTOR 13A; MONOCLONAL ANTIBODY; MULTIPROTEIN COMPLEX; PROTEIN BINDING;

AUTOREGULATION; BINDING SITE; CLINICAL DECISION MAKING; COMPLEX FORMATION; DRUG HALF LIFE; ENZYME BINDING; ENZYME SUBSTRATE COMPLEX; HEAVY CHAIN; IMMUNOGENICITY; LIGHT CHAIN; NONHUMAN; PHOSPHOLIPID VESICLE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; STOICHIOMETRY; ANIMAL; BLOOD; BLOOD CLOTTING; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; ENZYME ACTIVATION; ENZYME SPECIFICITY; HEMOPHILIA A; HUMAN; METABOLISM;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOOD COAGULATION; DRUG DISCOVERY; ENZYME ACTIVATION; FACTOR IX; FACTOR VIII; FACTOR X; FACTOR XIIIA; HEMOPHILIA A; HUMANS; MULTIPROTEIN COMPLEXES; PROTEIN BINDING; SUBSTRATE SPECIFICITY;

EID: 85037622811     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-08-801662     Document Type: Review

References (55)

1. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992;232(1):25-32.
2. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535-544.
3. Gouw SC, van der Bom JG, Ljung R, et al. PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368(3):231-239.
4. Calvez T, Chambost H, Claeyssens-Donadel S, et al. FranceCoag Network. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood. 2014;124(23):3398-3408.
5. Peyvandi F, Mannucci PM, Garagiola I, et al. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A. N Engl J Med. 2016; 374(21):2054-2064.
6. Eckhardt CL, van Velzen AS, Peters M, et al. INSIGHT Study Group. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood. 2013;122(11): 1954-1962.
7. van Velzen AS, Eckhardt CL, Hart DP, et al. INSIGHT study group. Inhibitors in nonsevere haemophilia A: outcome and eradication strategies. Thromb Haemost. 2015;114(1):46-55.
8. Mahlangu J, Powell JS, Ragni MV, et al. A-LONG Investigators. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123(3):317-325.
9. Konkle BA, Stasyshyn O, Chowdary P, et al. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015;126(9):1078-1085.
10. Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13(5): 743-754.
11. Sehgal A, Barros S, Ivanciu L, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015;21(5):492-497.
12. Kitazawa T, Igawa T, Sampei Z, et al. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med. 2012;18(10):1570-1574.
13. Muto A, Yoshihashi K, Takeda M, et al. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A. Blood. 2014;124(20):3165-3171.
14. Uchida N, Sambe T, Yoneyama K, et al. A first-inhuman phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects. Blood. 2016;127(13):1633-1641.
15. Shima M, Hanabusa H, Taki M, et al. Factor VIII-mimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med. 2016;374(21): 2044-2053.
16. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809-818.
17. Rotblat F, O’Brien DP, O’Brien FJ, Goodall AH, Tuddenham EG. Purification of human factor VIII: C and its characterization by Western blotting using monoclonal antibodies. Biochemistry. 1985; 24(16):4294-4300.
18. Andersson LO, Forsman N, Huang K, et al. Isolation and characterization of human factor VIII: molecular forms in commercial factor VIII concentrate, cryoprecipitate, and plasma. Proc Natl Acad Sci USA. 1986;83(9):2979-2983.
19. Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing, and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem. 1988;263(13):6352-6362.
20. Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. Blood. 2016; 128(16):2007-2016.
21. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry. 1986;25(2):505-512.
22. Leyte A, van Schijndel HB, Niehrs C, et al. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem. 1991; 266(2):740-746.
23. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood. 1998;92(11): 3983-3996.
24. Mertens K, Bertina RM. Activation of human coagulation factor VIII by activated factor X, the common product of the intrinsic and the extrinsic pathway of blood coagulation. Thromb Haemost. 1982;47(2):96-100.
25. Kamikubo Y, Mendolicchio GL, Zampolli A, et al. Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex. Blood. 2017; 130(14):1661-1670.
26. Lenting PJ, Christophe OD, Guéguen P. The disappearing act of factor VIII. Haemophilia. 2010; 16(102):6-15.
27. Mertens K, Celie PH, Kolkman JA, Lenting PJ. Factor VIII-factor IX interactions: molecular sites involved in enzyme-cofactor complex assembly. Thromb Haemost. 1999;82(2):209-217.
28. Spaargaren J, Giesen PL, Janssen MP, Voorberg J, Willems GM, van Mourik JA. Binding of blood coagulation factor VIII and its light chain to phosphatidylserine/phosphatidylcholine bilayers as measured by ellipsometry. Biochem J. 1995; 310(Pt 2):539-545.
29. Mertens K, Cupers R, Van Wijngaarden A, Bertina RM. Binding of human blood-coagulation Factors IXa and X to phospholipid membranes. Biochem J. 1984;223(3):599-605.
30. Lenting PJ, Donath MJ, van Mourik JA, Mertens K. Identification of a binding site for blood coagulation factor IXa on the light chain of human factor VIII. J Biol Chem. 1994;269(10):7150-7155.
31. Duffy EJ, Parker ET, Mutucumarana VP, Johnson AE, Lollar P. Binding of factor VIIIa and factor VIII to factor IXa on phospholipid vesicles. J Biol Chem. 1992;267(24):17006-17011.
32. Venkateswarlu D. Structural insights into the interaction of blood coagulation co-factor VIIIa with factor IXa: a computational protein-protein docking and molecular dynamics refinement study. Biochem Biophys Res Commun. 2014; 452(3):408-414.
33. Fay PJ, Beattie TL, Regan LM, O’Brien LM, Kaufman RJ. Model for the factor VIIIa-dependent decay of the intrinsic factor Xase. Role of subunit dissociation and factor IXa-catalyzed proteolysis. J Biol Chem. 1996;271(11):6027-6032.
34. Fay PJ, Koshibu K. The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem. 1998;273(30):19049-19054.
35. Kolkman JA, Lenting PJ, Mertens K. Regions 301-303 and 333-339 in the catalytic domain of blood coagulation factor IX are factor VIII-interactive sites involved in stimulation of enzyme activity. Biochem J. 1999;339(Pt 2):217-221.
36. Kolkman JA, Christophe OD, Lenting PJ, Mertens K. Surface loop 199-204 in blood coagulation factor IX is a cofactor-dependent site involved in macromolecular substrate interaction. J Biol Chem. 1999;274(41):29087-29093.
37. Kolkman JA, Mertens K. Insertion loop 256-268 in coagulation factor IX restricts enzymatic activity in the absence but not in the presence of factor VIII. Biochemistry. 2000;39(25):7398-7405.
38. Lapan KA, Fay PJ. Interaction of the A1 subunit of factor VIIIa and the serine protease domain of factor X identified by zero-length cross-linking. Thromb Haemost. 1998;80(3):418-422.
39. Lapan KA, Fay PJ. Localization of a factor X interactive site in the A1 subunit of factor VIIIa. J Biol Chem. 1997;272(4):2082-2088.
40. Takeyama M, Wakabayashi H, Fay PJ. Factor VIII light chain contains a binding site for factor X that contributes to the catalytic efficiency of factor Xase. Biochemistry. 2012;51(3):820-828.
41. Sampei Z, Igawa T, Soeda T, et al. Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One. 2013;8(2):e57479.
42. Kitazawa T, Esaki K, Tachibana T, et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. Thromb Haemost. 2017;117(7):1348-1357.
43. Elödi S, Váradi K. Activation of clotting factors in prothrombin complex concentrates as demonstrated by clotting assays for factors IXa and Xa. Thromb Res. 1978;12(5):797-807.
44. Hultin MB. Activated clotting factors in factor IX concentrates. Blood. 1979;54(5):1028-1038.
45. Mertens K, Bertina RM. The contribution of Ca21 and phospholipids to the activation of human blood-coagulation factor X by activated factor IX. Biochem J. 1984;223(3):607-615.
46. Nesheim ME, Pittman DD, Wang JH, Slonosky D, Giles AR, Kaufman RJ. The binding of 35S-labeled recombinant factor VIII to activated and unactivated human platelets. J Biol Chem. 1988; 263(31):16467-16470.
47. Agbani EO, van den Bosch MT, Brown E, et al. Coordinated membrane ballooning and procoagulant spreading in human platelets. Circulation. 2015;132(15):1414-1424.
48. Gilbert GE, Novakovic VA, Shi J, Rasmussen J, Pipe SW. Platelet binding sites for factor VIII in relation to fibrin and phosphatidylserine. Blood. 2015;126(10):1237-1244.
49. Rosenberg JS, McKenna PW, Rosenberg RD. Inhibition of human factor IXa by human antithrombin. J Biol Chem. 1975;250(23): 8883-8888.
50. Schmaier AH, Dahl LD, Rozemuller AJ, et al. Protease nexin-2/amyloid beta protein precursor. A tight-binding inhibitor of coagulation factor IXa. J Clin Invest. 1993;92(5):2540-2545.
51. Soeda T, Kitazawa T, Muto A, et al. In vitro characterization of ACE910, a humanized bispecific antibody to factors IXa and X. Haemophilia. 2014;20(suppl 3):77.
52. den Uijl I, Biesma D, Grobbee D, Fischer K. Outcome in moderate haemophilia. Blood Transfus. 2014;12(Suppl 1):s330-s336.
53. Stoylova SS, Lenting PJ, Kemball-Cook G, Holzenburg A. Electron crystallography of human blood coagulation factor VIII bound to phospholipid monolayers. J Biol Chem. 1999; 274(51):36573-36578.
54. Stoilova-McPhie S, Villoutreix BO, Mertens K, Kemball-Cook G, Holzenburg A. 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood. 2002;99(4):1215-1223.
55. Meems H, Meijer AB, Cullinan DB, Mertens K, Gilbert GE. Factor VIII C1 domain residues Lys 2092 and Phe 2093 contribute to membrane binding and cofactor activity. Blood. 2009; 114(18):3938-3946.